John Somberg to United States Food and Drug Administration
This is a "connection" page, showing publications John Somberg has written about United States Food and Drug Administration.
Connection Strength
5.072
-
Drug shortages and ensuring the U.S. supply of needed pharmaceuticals. Am J Ther. 2012 Mar; 19(2):65.
Score: 0.415
-
Has the food and drug administration changed the drug approval process? Am J Ther. 2011 May; 18(3):179.
Score: 0.391
-
FDA user fees and innovation. Am J Ther. 2008 Mar-Apr; 15(2):97.
Score: 0.314
-
Patent foramen ovale closure devices: thoughts from the circulatory device advisory panel. Am J Cardiol. 2007 Sep 01; 100(5):905-6.
Score: 0.299
-
The drug safety review process. Am J Ther. 2007 Mar-Apr; 14(2):119.
Score: 0.293
-
The report of the Institute of Medicine on drug safety. Am J Ther. 2007 Jan-Feb; 14(1):1-2.
Score: 0.290
-
An opportunity to distance the FDA from Washington politics. Am J Ther. 2005 Nov-Dec; 12(6):475.
Score: 0.267
-
The provisional approval step. Am J Ther. 2005 Jan-Feb; 12(1):1-2.
Score: 0.252
-
Restricting physician prescribing. Am J Ther. 2002 Sep-Oct; 9(5):369.
Score: 0.215
-
Are we overregulated? Am J Ther. 2001 Jan-Feb; 8(1):1-2.
Score: 0.191
-
The Bretylium Saga: A Novel "Old Drug" for Cardiac Resuscitation. Am J Cardiol. 2020 05 15; 125(10):1596-1598.
Score: 0.181
-
Assessment of cardiovascular and noncardiovascular medical device recalls. Am J Cardiol. 2014 Jun 01; 113(11):1899-903.
Score: 0.119
-
The conflict of interest charade. Am J Ther. 2013 Nov-Dec; 20(6):591.
Score: 0.116
-
Proposed accelerated FDA approvals for special medical use. Am J Ther. 2012 Nov; 19(6):393-4.
Score: 0.109
-
Sharing regulatory review costs. J Clin Pharmacol. 1992 Oct; 32(10):867.
Score: 0.108
-
Making America more competitive: a paradigm shift in drug and device development. Am J Ther. 2012 Sep; 19(5):315-6.
Score: 0.107
-
The device development pinata. Am J Ther. 2011 Sep; 18(5):339.
Score: 0.100
-
Inappropriate attack on device development. Am J Ther. 2011 Mar-Apr; 18(2):91.
Score: 0.097
-
The Food and Drug Administration's paternalism. Am J Ther. 2010 Nov-Dec; 17(6):533-4.
Score: 0.095
-
Developing a safe intravenous sotalol dosing regimen. Am J Ther. 2010 Jul-Aug; 17(4):365-72.
Score: 0.092
-
Device safety and effectiveness. Am J Ther. 2010 Jul-Aug; 17(4):357.
Score: 0.092
-
The extrapolation of study results in the device approval process. Am J Cardiol. 2009 May 01; 103(9):1323-4.
Score: 0.084
-
Securing the US pharmaceutical supply. Am J Ther. 2008 May-Jun; 15(3):197.
Score: 0.079
-
Mandatory post marketing studies. Am J Ther. 2007 Jul-Aug; 14(4):321.
Score: 0.075
-
Off-label promotion. Am J Ther. 2006 Sep-Oct; 13(5):387.
Score: 0.071
-
Nesiritide: the wrong controversy. Am J Ther. 2005 Sep-Oct; 12(5):377-8.
Score: 0.066
-
Lessons learned from the COX-2 advisory hearings. Am J Ther. 2005 Mar-Apr; 12(2):105.
Score: 0.064
-
The politics of therapeutics. Am J Ther. 2004 Nov-Dec; 11(6):422.
Score: 0.062
-
Drug trial registries. Am J Ther. 2004 Sep-Oct; 11(5):327.
Score: 0.062
-
Should statins go OTC. Am J Ther. 2004 Jan-Feb; 11(1):1-2.
Score: 0.059
-
Therapeutics, drug pricing and innovation. Am J Ther. 2003 Nov-Dec; 10(6):381.
Score: 0.058
-
Clinical trials registries. Am J Ther. 2003 Sep-Oct; 10(5):309-10.
Score: 0.058
-
Old drugs, new bottles, therapeutic advantage? Am J Ther. 2002 Jul-Aug; 9(4):273-4.
Score: 0.053
-
Proposed product labeling changes: does it really matter? Am J Ther. 2001 May-Jun; 8(3):145-6.
Score: 0.049
-
Medical judgment and therapeutics. Am J Ther. 1999 Nov; 6(6):291-2.
Score: 0.044
-
Advances in cardiovascular pharmacology: protocol design and methodology--the US regulatory process. Am J Ther. 1999 May; 6(3):175-8.
Score: 0.043